Background The response rate to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) varies significantly among individuals. Cancer-associated macrophages (TAMs) are key components of the tumor immune microenvironment (TIME), influencing tumor proliferation, metastasis, immune cell recruitment, and activation through diverse mechanisms. Their high heterogeneity, particularly in the context of immunotherapy, warrants further investigation. Methods We integrated single-cell and spatial transcriptomic data from the same patients using ISCHIA to construct nine spatial niches(local cellular communities). The composition of these niches was compared across different spatial regions and between samples with varying ICB treatment responses. CYP27A1 + TAMs, identified as critical in ICB-responsive groups, were validated through external cohorts, immunohistochemistry, immunofluorescence, and in vivo experiments. Results Spatial niche analysis revealed that niche 9, which was enriched with effector cells, was found exclusively in ICB responders. CYP27A1 + TAMs were a key component of this niche, recruiting CD8 + T cells via antigen presentation and chemokine secretion, thereby improving patient prognosis. Based on this, we developed an accurate prognostic model. Following ICB treatment, these macrophages exhibited further activation of LXR and enhanced anti-apoptotic capabilities. In vivo and morphological experiments demonstrated that CYP27A1 + TAMs effectively suppressed tumor growth and increased CD8 + T cells infiltration in the TIME. Conclusion This study highlights the importance of spatial niches in understanding the TIME of NSCLC and predicting ICB responses. CYP27A1 + TAMs and their downstream LXR pathway provide a novel research direction for exploring potential biomarkers for personalized NSCLC management.
Liu et al. (Thu,) studied this question.